Heparin-induced thrombocytopenia: pathogenesis and management. - Wikidata - awgldk - TriplyDB

Heparin-induced thrombocytopenia: pathogenesis and management.

Heparin-induced thrombocytopenia: pathogenesis and management.

http://www.wikidata.org/entity/Q33348049

about

Heparin-induced thrombocytopenia in the ICU: an overview Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients New anticoagulants for the prevention and treatment of venous thromboembolism Heparin-induced thrombocytopenia: an update Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums Idiosyncratic adverse drug reactions: current concepts HITlights: a career perspective on heparin-induced thrombocytopenia Fcγ receptors and ligands and cardiovascular disease Coagulation abnormalities in critically ill patients An Efficient Pattern Mining Approach for Event Detection in Multivariate Temporal Data.A Temporal Pattern Mining Approach for Classifying Electronic Health Record Data.Low-molecular-weight heparin-induced thrombocytopenia in a child.Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation.Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.Heparin overview and issues.Unfractionated heparin: focus on a high-alert drug.Towards a diagnosis of heparin-induced thrombocytopenia after cardiopulmonary bypass.Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.Diagnosis and management of heparin-induced thrombocytopenia.Bivalirudin: a review.Bilateral renal artery thrombosis due to heparin-induced thrombocytopenia-thrombosis syndrome. Successful treatment with longterm application of lepirudin.Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.Safety and efficacy of danaparoid (Orgaran) use in children.Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.The management of heparin-induced thrombocytopenia.Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient.Heparin-induced thrombocytopenia: recent experience in a large teaching hospital.Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.A fatal case of enoxaparin induced skin necrosis and thrombophilia.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Report of a patient with heparin-induced thrombocytopenia type II associated with IgA antibodies only.Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study.Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia: treatment options and special considerations.Heparin-induced thrombocytopenia and recent advances in its therapy.

P2860

Q21194907-B6417E6E-8DBC-4200-A063-5F628F984D9F Q24200589-D71315B5-659C-4DD7-A7B6-5A0906B0F51C Q24241979-2C272D27-90C9-47ED-A529-47F5A7AFA5EB Q24681351-B4F4BEE8-49F1-448C-AA65-50BEC001F272 Q24815767-488017F8-229B-48FB-ADEB-4F89BAB3A958 Q26751442-55B252DB-2A6A-4A7F-8543-50A64CCE443A Q26799395-EE8A0A23-579A-4B4B-93B3-61BF7637017F Q26824391-0D64E701-6420-4559-BD9E-E188235DF0CC Q26828351-53356D49-9F51-40AA-824F-A78E38DB93F9 Q27021449-C68C80C9-5417-402B-98A0-2D2BB3C97745 Q28199912-2DFB6140-3526-49AD-B12E-47A9FECB9C31 Q30277776-E419705F-3431-4E00-947D-69731E651777 Q30859736-83B35E8F-423E-4D4F-8F6A-FF363B17E367 Q33358704-42252EDB-18D7-453E-91F9-41375DFE7A86 Q33359715-50378CE9-BF62-4FDD-8242-718532EF19EF Q33360104-F5401EA0-8712-4D9C-BB81-9AA6484B5954 Q33362184-D8271895-93A9-4AC5-B9F8-03D077E2C9FC Q33362316-0FDA9A6F-84FF-431D-B868-7CB50D7967B8 Q33362322-02E9BFC4-69E7-406B-9A56-5CED39522C17 Q33363740-A8D71CD9-F3BA-4F4D-81B8-F919A271EC83 Q33364229-1E4FA2CC-B4E3-4B6C-B785-20AA3C01B654 Q33365296-AD160792-9B31-41CC-8878-9ACB6C8BE9DB Q33365985-5C884FB0-30B3-4AAB-921A-FA95B3BB11F2 Q33367230-0949B56A-165A-4238-8161-B7A9E32C4B52 Q33370189-941E27E7-99CA-4179-B928-CC0AD78B4CEF Q33370224-878FBCEB-6DD9-4926-B256-6A2D7581BBF9 Q33370473-E7A7CB15-E3F7-43AA-8A1F-DEC6ABF4E15C Q33370615-7B8B079C-696D-4843-BC68-C768164919DC Q33370696-C0C01540-DBE3-4182-B964-F445D1355D5D Q33371013-6B1209FB-8E41-4806-A17E-24B3AFF85259 Q33371291-B209CC5B-F93E-42D2-9E3A-2FCC2D069155 Q33371593-75A7DF94-ACF9-4E80-9E0D-0BDD42028414 Q33371628-7D56C6C1-9967-4AEC-87AB-D24F48ABF3B7 Q33372023-094E67E3-F08A-4429-89C2-B6FD52FB819D Q33372266-C88483E1-C7BC-4F01-979B-32E6406C996B Q33372569-A1285E1A-7816-4330-9AEA-D953A5C22607 Q33373310-03337508-F1A9-4E96-A307-9A5A8177DA64 Q33374563-787ADE29-15FC-49CD-BC59-6B4A8BB10570 Q33374658-4DA8270F-7FF7-4834-AE15-DAACF643A3E2 Q33377436-45D61FE8-3209-42F3-9366-C6833A632A00

P2860

Heparin-induced thrombocytopenia: pathogenesis and management.

http://www.wikidata.org/entity/Q33348049

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

name

Heparin-induced thrombocytopenia: pathogenesis and management.

@ast

Heparin-induced thrombocytopenia: pathogenesis and management.

@en

type

label

Heparin-induced thrombocytopenia: pathogenesis and management.

@ast

Heparin-induced thrombocytopenia: pathogenesis and management.

@en

prefLabel

Heparin-induced thrombocytopenia: pathogenesis and management.

@ast

Heparin-induced thrombocytopenia: pathogenesis and management.

@en

P1433

Q33348049-3F082456-FDDD-461D-B61F-262EF9131A54

P1476

Q33348049-AD881572-C43B-4C24-85F1-69F9421C1958

P2860

Q33348049-03F2E356-E5C6-4EC6-8A10-3276539B1007

Q33348049-089BE951-24A4-4086-8886-99A04ECB7C74

Q33348049-09065297-78AD-49F0-B658-0A4FE03F024C

Q33348049-140D354D-2C40-450E-BA0A-3F7D1CD73D09

Q33348049-14C7489D-C84F-4EC3-8E7F-4DB31DF63118

Q33348049-15FA7A2B-DF2C-4581-9DD3-ECBC1F9FBEF0

Q33348049-26C0B9DF-4D74-4E7F-90FA-0365A4E3EAB6

Q33348049-2E1A3C79-0C1B-4691-9FC9-F91542F1C177

Q33348049-2FE78A94-D334-4A22-AF17-333994F792D1

Q33348049-3BF32A19-A0A7-4EB4-88B3-4B6289157785

P304

Q33348049-DF6CA469-BDB0-4A0E-BFDA-02219455418E

P31

Q33348049-EBF0FC91-A1E2-4107-8AF1-4C4BF8845934

P356

Q33348049-F0802D62-49E4-489E-8F7E-4A94073087C0

P407

Q33348049-F19778DC-1DD9-46F9-8738-B5EDABE6106A

P433

Q33348049-93C3EFBA-1A50-414A-8756-9100B8FD54A0

P478

Q33348049-FD304F73-FDEA-4268-827C-03515D0FD982

P50

Q33348049-A9CF5859-BE03-4F37-98DE-C2E95249E98C

P577

Q33348049-4B22096F-7AAD-4391-B717-B2079BC30F3C

P5875

Q33348049-238961CE-484A-459F-891D-56A7C57B59AA

P698

Q33348049-1C986199-D15C-4C27-84A3-FF63EACF0F61

P921

Q33348049-04D1C3AB-EB55-488E-828D-19CE6B2C42E8

Q33348049-5721C2E3-FFD9-4B9B-A380-AAFDEC3B5F5F

P356

J.1365-2141.2003.04334.X

P1433

British Journal of Haematology

P1476

Heparin-induced thrombocytopenia: pathogenesis and management.

@en

P2860

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

Further characterization of antibody and antigen in heparin-induced thrombocytopenia.

Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature.

Identification of T cells responding to a self-protein modified by an external agent.

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

Temporal aspects of heparin-induced thrombocytopenia.

P304

535-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2003.04334.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Theodore E Warkentin

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10755642

http://www.w3.org/2001/XMLSchema#string

P698

12752095

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia